-
Security Type
-
Convertible Note
-
Categories
-
Technology, Healthcare & Medical, Community & Lifestyle
-
Min Investment
-
$100
-
Expected Close Date
-
April 29, 2024
-
Target Raise
-
$50.00K-$120.00K
-
No. Investors
-
13
-
Security Price
-
$1
- Number of Employees
- 2
- Cash
- $3,290
- Revenue
- $0
- Short Term Debt
- $4,509
- Cost of Goods
- $0
- Long Term Debt
- $8,518
- Net Income
- $-4,932
Key Deal Facts
We proactively bank cancer patient immune cells for cell therapy (incl. pre-chemo) at no cost
With us, industry can now pre-enroll patients for studies and manufacture with "off-the-shelf" cells
Our unique platform generates invaluable large-format, patient records-linked research biomaterial
Free-to-patient model fueled by PRO-Aph specimen sales: LOIs reflect ~$0.3m+/pt in potential demand
Launch network incl. leaders from Genentech, Penn, Be The Match, xCures, +dozens in active pipeline
Initial oncologist support and collection (apheresis) sites expected in Seattle and Houston
Proudly endorsed by the Emily Whitehead Foundation (https://emilywhiteheadfoundation.org/)
Management Team / Advisory Board Bios
Paul Chun Chief Financial Officer, Co-Founder~20 year biotech veteran with background in investment research, capital markets, corporate development, and finance, including public biotech Board of Directors. Track record of several IPOs, financings, licensing, etc., incl. in cancer immunotherapy., Brad Heller Chief Executive Officer, FounderUCSF-trained neuro and cell biology specialist with biopharma startup experience across CAR-TCR and drug discovery. Finally got fed up with seeing curative cell therapies get stuck behind apheresis appointment backlogs and chemo-cooked cells.